National Action Plan For The MHPSS Response To COVID-19

National Action Plan for the MHPSS Response to COVID-19

This action plan was developed as part of the national response to the COVID-19 outbreak. It aims at comprehensively addressing the MHPSS aspects of the COVID-19 outbreak in Lebanon for all persons living in the country. It was developed by the MOPH-National Mental Health Programme (NMHP) with WHO and UNICEF, in line with the IASC Briefing note on addressing mental health and psychosocial aspects of COVID-19 Outbreak- version 1.0 and the local needs, health system and national mental health strategy.

Goals:

Promote mental health and mitigate COVID-19 related stressors including stigma and discrimination against persons affected and health workers.
Provide mental health support to the persons in quarantine in the hospital or at home and their families.
Support the mental health of health workers and first responders in the response.
Ensure continuity of mental health care for persons using mental health services in line with IPC guidelines.

To view the action plan, click here: National Action Plan for MHPSS Response to COVID-19

...

All

ATC	Name	B/G ↑	Ingredients	Dosage	Form	Price
L01EA04	BOSULIF	B	Bosutinib - 100mg	100mg	Tablet, film coated	L.L
D07AC01	BETNOVATE	B	Betamethasone - 0.1%	0.1%	Solution	235,172 L.L
C09BA04	BI-PRETERAX ARGININE	B	Perindopril arginine - 5mg, Indapamide - 1.25mg		Tablet, film coated	452,875 L.L
D07AC01	BETNOVATE	B	Betamethasone (valerate) - 0.1%	0.1% w/w	Cream	279,519 L.L
C09BA04	BI-PRETERAX ARGININE	B	Perindopril arginine - 10mg, Indapamide - 2.5mg		Tablet, film coated	765,990 L.L
D07AC01	BETNOVATE	B	Betamethasone (valerate) - 0.1%	0.1% w/w	Ointment	279,519 L.L
L01DC01	BLEOCIN	B	Bleomycin (sulfate) - 15U	15U	Injectable lyophilised powder for solution	2,109,833 L.L
N07BC01	BUVIDAL	B	Buprenorphine - 8mg	8mg	Injectable solution prolonged release	8,524,771 L.L
N07BC01	BUVIDAL	B	Buprenorphine - 16mg	16mg	Injectable solution prolonged release	8,524,771 L.L
N07BC01	BUVIDAL	B	Buprenorphine - 24mg	24mg	Injectable solution prolonged release	8,524,771 L.L
N07BC01	BUVIDAL	B	Buprenorphine - 32mg	32mg	Injectable solution prolonged release	8,524,771 L.L
N07BC01	BUVIDAL	B	Buprenorphine - 64mg	64mg	Injectable solution prolonged release	34,835,645 L.L
M05BA04	BINOSTO	B	Alendronate sodium - 70mg	70mg	Tablet, effervescent	1,709,368 L.L
N07BC01	BUVIDAL	B	Buprenorphine - 96mg	96mg	Injectable solution prolonged release	34,835,645 L.L
M05BA06	BONVIVA	B	Ibandronic acid - 150mg	150mg	Tablet, film coated	1,265,900 L.L
N07BC01	BUVIDAL	B	Buprenorphine - 128mg	128mg	Injectable solution prolonged release	34,835,645 L.L
M05BA06	BONDRONAT	B	Ibandronic acid (monosodium monohydrate) - 6mg/6ml	6mg/6ml	Injectable concentrated powder for solution	24,963,868 L.L
M05BA06	BONVIVA	B	Ibandronic acid - 3mg/3ml	3mg/3ml	Injectable solution	3,144,591 L.L
N07CA01	BETASERC	B	Betahistine dihydrochloride - 16mg	16mg	Tablet	1,623,708 L.L
J05AR20	BIKTARVY	B	Bictegravir - 50mg, Emtricitabine - 200mg, Tenofovir alafenamide - 25mg		Tablet, film coated	76,569,138 L.L
A07BA01	BIOCARBON	B	Activated charcoal - 250mg	250mg	Tablet	1,361,312 L.L
G04BD12	BETMIGA	B	Mirabegron - 50mg	50mg	Tablet, prolonged release	3,758,727 L.L
A07EA06	BUDENOFALK	B	Budesonide - 3mg	3mg	Capsule	8,554,692 L.L
C03CA02	BURINEX	B	Bumetanide - 1mg	1mg	Tablet	335,961 L.L
C03CA02	BURINEX	B	Bumetanide - 5mg	5mg	Tablet	1,054,916 L.L
N05AX13	BYANNLI	B	Paliperidone - 1000mg	1000mg	Injectable suspension, prolonged release	141,224,257 L.L
L01EA04	BOSULIF	B	Bosutinib - 100mg	100mg	Tablet, film coated	35,663,747 L.L
N05AX13	BYANNLI	B	Paliperidone - 700mg	700mg	Injectable suspension, prolonged release	96,913,176 L.L
L01EA04	BOSULIF	B	Bosutinib - 400mg	400mg	Tablet, film coated	123,564,667 L.L
L01EA04	BOSULIF	B	Bosutinib - 500mg	500mg	Tablet, film coated	154,453,246 L.L

...